Objective: Lifestyle intervention with diet modification and increase in physical activity is effective for reducing hepatic steatosis in patients with non-alcoholic fatty liver disease (NAFLD). However, for a similar weight loss, there is a large variability in the change in liver fat. We hypothesised that cardiorespiratory fitness may predict the response to the intervention.
Design: Longitudinal study with increase in physical activity and diet modification.
Setting: University teaching hospital.
Patients: 50 adults with NAFLD and 120 controls at risk for metabolic diseases.
Main outcome measures: Total-, subcutaneous abdominal- and visceral adipose tissue by magnetic resonance tomography, liver fat by 1HMR spectroscopy and cardiorespiratory fitness (VO2,max) by a maximal cycle exercise test at baseline and after 9 months of follow-up.
Results: In all subjects total-, subcutaneous abdominal- and visceral adipose tissue decreased and fitness increased (all p<0.0001) during the intervention. The most pronounced changes were found for liver fat (−31%, p<0.0001). Among the parameters predicting the change in liver fat, fitness at baseline emerged as the strongest factor, independently of total- and visceral adipose tissue as well as exercise intensity (p = 0.005). In the group of subjects with NAFLD at baseline, a resolution of NAFLD was found in 20 individuals. For 1 standard deviation increase in VO2,max at baseline the odds ratio for resolution of NAFLD was 2.79 (95% confidence interval, 1.43–6.33).
Conclusions: Cardiorespiratory fitness, independently of total adiposity, body fat distribution and exercise intensity, determines liver fat content in humans, suggesting that fitness and liver fat are causally related to each other. Moreover, measurement of fitness at baseline predicts the effectiveness of a lifestyle intervention in reducing hepatic steatosis in patients with NAFLD.
Statistics from Altmetric.com
Funding The study was supported by grants from the Deutsche Forschungsgemeinschaft (KFO 114 and a Heisenberg-Grant to NS, STE 1096/1-1) and the European Community’s FP6 EUGENE2 (LSHM-CT-2004-512013). The supporters had no influence on the study design and on the collection, analysis, and interpretation of data.
Competing interests None.
Ethics approval The local medical ethics committee approved the protocol on 20 December 2002.
▸ A supplementary figure is published online only at http://gut.bmj.com/content/vol58/issue9
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.